NOVARTIS

Novartis to present over 65 abstracts at ASH and SABCS, including 96-week Scemblix results and 4-year Kisqali analysis. The presentations highlight advancements in hematologic diseases and cancers, emphasizing earlier disease stages and new treatment options.

DelveInsight's 'Nasal Polyposis Pipeline Insight, 2024' report details the global development of 4+ Nasal Polyposis treatment therapies by 4+ key companies, including GlaxoSmithKline, Novartis, and AstraZeneca. Emerging therapies like Fasenra and Tezepelumab are expected to impact the market. The report covers clinical trials, mechanisms of action, route of administration, and market dynamics.

CRISPR Therapeutics stock is down 47% since March due to slow Casgevy launch, but it has five other therapy candidates in clinical-stage testing. Despite slow sales, Casgevy's potential and a $1.9 billion cash reserve make CRISPR Therapeutics a risky but potentially lucrative investment.

Novartis acquires Kate Therapeutics for $1.1B, Barclays predicts challenging 2025 for European pharma, Trump picks surgeon Martin Makary to lead FDA, Novartis partners with Ratio Therapeutics for up to $745M, Kyowa Kirin pays Kura Oncology $330M upfront for leukemia drug rights, global measles cases rise 20% to 10.3 million, Brookfield considers €7B bid for Grifols, Bavarian Nordic's 2025 order book reaches €320M, FDA supports REGENXBIO's Duchenne muscular dystrophy gene therapy, Merck's subcutaneous Keytruda matches infused version, Syndax Pharmaceuticals secures FDA approval for Revuforj, Aclaris Therapeutics licenses 2 antibodies from Biosion for over $40M upfront, Sandoz to cut 10% of workforce in France, Incyte halts testing and discontinues drugs, Sage Therapeutics discontinues dalzanemdor, Johnson & Johnson and Merck announce job cuts in China, Samsung Biologics signs $668M contracts, FDA grants accelerated approval to Jazz Pharmaceuticals' Ziihera, Lexicon Pharmaceuticals cuts 60% of workforce, Halozyme withdraws €2B bid for Evotec, mpox epidemic overwhelms hospitals in Kinshasa.

Tango Therapeutics reports Q3 2024 financials, highlighting progress in PRMT5 inhibitor TNG462 clinical trials, including positive data in pancreatic and NSCLC. The company plans to advance TNG462 into combination trials with RAS(ON) inhibitors and other treatments, expecting enrollment in 1H 2025. TNG908 trial enrollment is halted to focus on TNG462. Tango also announces the appointment of Dr. Maeve Waldron-Lynch as SVP, Head of Clinical Development.